Pasar al contenido principal

Complicaciones cardiovasculares de la Enfermedad Renal Crónica.

FJCI-2016-29050

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Juan de la Cierva Formación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA BIOMEDICA DE LLEIDA, FUNDACIO PRIVADA DR. PIFARRE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment"

  • Ruiz-Ortega, Marta
  • Rodrigues-Diez, Raul
  • Lavoz, Carolina
  • Rayego Mateos, Sandra
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine., Editors are funding by Grants from the Instituto de Salud Carlos III(ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R-O), Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R-O); the Jose Castillejo grant (CAS19/00133 to R.R.R-D); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of SR-M (FJCI-2016-29050); Sociedad Espanola de Nefrologia (S.E.N. to M.R-O). Grants PAI 82140017 to C.L. of Chile; IMPROVE-PD project ("Identification and Management of Patients atRisk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

IL-17A as a potential therapeutic target for patients on peritoneal dialysis

  • Marchant, Vanessa
  • Tejera Muñoz, Antonio
  • Marquez Exposito, Laura
  • Rayego Mateos, Sandra
  • Rodrigues-Diez, Raul
  • Tejedor, Lucia
  • Santos Sanchez, Laura
  • Egido, Jesús
  • Valdivielso Revilla, José Manuel
  • Fraser, Donald J.
  • López Cabrera, Manuel
  • Selgas, Rafael
  • Ruiz-Ortega, Marta
Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, gamma delta T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 to M.R.-O.; PI17/01495, DTS17/00203, and DTS19/00093 to J.E.; PI16/02057 and PI19/00815 to A.O.; PI 15/00120 to R.S; PI18/0610 to J.M.V.; and Red de Investigacion Renal (REDINREN): RD16/0009 to M.R.-O., A.O., R.S., and J.M.V.); by Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O. and B2017/BMD-3686 CIFRA2-CM to A.O.); by the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supporting the salary of S.R.-M. (FJCI-2016-29050); by "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); by Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.); by ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 toA.O; by IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") with funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 812699 to M.R.O., M.L.-C., and D.F.; and by the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) (PID2019-110132RB-I00) to M.L.-C.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Could IL-17A be a novel therapeutic target in diabetic nephropathy?

  • Lavoz, Carolina
  • Rayego Mateos, Sandra
  • Orejudo, Macarena
  • Opazo Rios, Lucas
  • Marchant, Vanessa
  • Marquez Exposito, Laura
  • Tejera Muñoz, Antonio
  • Navarro González, Juan F.
  • Droguett, Alejandra
  • Ortiz, Alberto
  • Egido, Jesús
  • Mezzano, Sergio
  • Rodrigues-Diez, Raul
  • Ruiz-Ortega, Marta
Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy., This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R.-O., PI17/01495, DTS17/00203 and DTS19/00093 to J.E., PI16/02057, PI19/00815 to A.O.); Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O., B2017/BMD-3686 CIFRA2-CM to A.O.); the Jose Castillejo grant (CAS19/00133 to R.R.R.-D.); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of S.R.-M. (FJCI-2016-29050); "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.). Grants Fondecyt 1160465 to S.M. and PAI 82140017 to C.L. of Chile; ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 to A.O.; IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Could IL-17A be a novel therapeutic target in diabetic nephropathy?

  • Lavoz, Carolina
  • Rayego Mateos, Sandra
  • Orejudo, Macarena
  • Opazo Rios, Lucas
  • Marchant, Vanessa
  • Marquez Exposito, Laura
  • Tejera Muñoz, Antonio
  • Navarro González, Juan F.
  • Droguett, Alejandra
  • Ortiz, Alberto
  • Egido, Jesús
  • Mezzano, Sergio
  • Rodrigues-Diez, Raul
  • Ruiz-Ortega, Marta
Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy., This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R.-O., PI17/01495, DTS17/00203 and DTS19/00093 to J.E., PI16/02057, PI19/00815 to A.O.); Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O., B2017/BMD-3686 CIFRA2-CM to A.O.); the Jose Castillejo grant (CAS19/00133 to R.R.R.-D.); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of S.R.-M. (FJCI-2016-29050); "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.). Grants Fondecyt 1160465 to S.M. and PAI 82140017 to C.L. of Chile; ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 to A.O.; IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

IL-17A as a potential therapeutic target for patients on peritoneal dialysis

  • Marchant, Vanessa
  • Tejera Muñoz, Antonio
  • Marquez Exposito, Laura
  • Rayego Mateos, Sandra
  • Rodrigues-Diez, Raul
  • Tejedor, Lucia
  • Santos Sanchez, Laura
  • Egido, Jesús
  • Valdivielso Revilla, José Manuel
  • Fraser, Donald J.
  • López Cabrera, Manuel
  • Selgas, Rafael
  • Ruiz-Ortega, Marta
Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, gamma delta T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 to M.R.-O.; PI17/01495, DTS17/00203, and DTS19/00093 to J.E.; PI16/02057 and PI19/00815 to A.O.; PI 15/00120 to R.S; PI18/0610 to J.M.V.; and Red de Investigacion Renal (REDINREN): RD16/0009 to M.R.-O., A.O., R.S., and J.M.V.); by Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O. and B2017/BMD-3686 CIFRA2-CM to A.O.); by the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supporting the salary of S.R.-M. (FJCI-2016-29050); by "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); by Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.); by ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 toA.O; by IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") with funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 812699 to M.R.O., M.L.-C., and D.F.; and by the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) (PID2019-110132RB-I00) to M.L.-C.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment"

  • Ruiz-Ortega, Marta
  • Rodrigues-Diez, Raul
  • Lavoz, Carolina
  • Rayego Mateos, Sandra
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine., Editors are funding by Grants from the Instituto de Salud Carlos III(ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R-O), Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R-O); the Jose Castillejo grant (CAS19/00133 to R.R.R-D); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of SR-M (FJCI-2016-29050); Sociedad Espanola de Nefrologia (S.E.N. to M.R-O). Grants PAI 82140017 to C.L. of Chile; IMPROVE-PD project ("Identification and Management of Patients atRisk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.